Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

This study has been completed.
Merck Sharp & Dohme Corp.
Information provided by:
NovaCardia, Inc. Identifier:
First received: September 7, 2005
Last updated: January 28, 2008
Last verified: January 2008
The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.

Condition Intervention Phase
Heart Failure, Congestive
Renal Insufficiency
Drug: KW-3902IV
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With Congestive Heart Failure (CHF) and Renal Impairment

Resource links provided by NLM:

Further study details as provided by NovaCardia, Inc.:

Primary Outcome Measures:
  • Comparison of KW-3902IV alone or with loop diuretic on renal function.

Estimated Enrollment: 30
Study Start Date: September 2005

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Stable congestive heart failure
  • Impaired renal function
  • Taking oral loop diuretic

Exclusion Criteria:

  • Acutely decompensated (unstable) and end stage heart failure
  • Diuretics other than loop diuretics
  • Pregnant or nursing
  • Inability to follow instructions
  • Participation in another clinical trial within past 30 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00159614

United States, California
San Diego, California, United States
United States, Maryland
Baltimore, Maryland, United States
United States, Massachusetts
Ayer, Massachusetts, United States
Boston, Massachusetts, United States
United States, Michigan
Kalamazoo, Michigan, United States
United States, Tennessee
Tullahoma, Tennessee, United States
Sponsors and Collaborators
NovaCardia, Inc.
Merck Sharp & Dohme Corp.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00159614     History of Changes
Other Study ID Numbers: CKI-203
Study First Received: September 7, 2005
Last Updated: January 28, 2008

Keywords provided by NovaCardia, Inc.:
renal insufficiency
heart failure, congestive

Additional relevant MeSH terms:
Heart Failure
Renal Insufficiency
Heart Diseases
Cardiovascular Diseases
Kidney Diseases
Urologic Diseases
Natriuretic Agents
Physiological Effects of Drugs
Sodium Potassium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017